Abstract 548: Association Between Serum Omentin-1 Level and Coronary Artery Disease: A Meta-Analysis
Background: In recent years, visceral adipose tissues and adipokines have been implicated to play a crucial role in the pathogenesis of atherosclerosis and coronary artery disease (CAD). Omentin-1(OM-1) is a novel adipokine shown to be associated with chronic inflammatory diseases, insulin resistance, obesity and carotid atherosclerosis. Recent studies have shown OM-1 as a modulator of vascular function via endothelium-dependent vasodilation. OM-1 plays a role in vascular inflammation as it suppresses cytokine-stimulated expression of adhesion molecules in endothelial cells. The association of CAD and OM-1 remains unclear. The aim of the present study is to conduct a meta-analysis to determine the relationship between serum OM-1 levels and CAD.
Methods: We searched MEDLINE, CIINHAL and COCHRANE databases for studies reporting serum OM-1 levels in the CAD and non-CAD study population. We included case controls, cohort and cross-sectional studies. We calculated the weighted standardized mean difference (SMD) in serum OM-1 levels between the CAD and control groups.
Results: Our search strategy yielded 31 articles and we included 5 case control and 1 cross-sectional study enrolling 844 participants. The median age of the CAD group was 64yrs (IQR 62.3 - 65.76) compared to 61.93yrs (IQR 60.18 - 62.97) in the control group. The median percentage of female population in the CAD group was 39.25(IQR 29.13 - 53.7) compared to 43.5(IQR 26.92 - 43.5) in the control group. The unweighted median serum OM-1 levels in the CAD group were 103.6ng/ml (IQR 39.2 - 110.91) compared to 130.9ng/ml (IQR 62.6 - 370.65) in the control group. The SMD of OM-1 level was -2.27 (95% CI -3.44, -1.09) p<0.001 comparing those in the CAD group and control group.
Conclusion: Serum OM-1 level is independently and negatively associated with CAD. Further studies are needed to define the role of OM-1 in the pathogenesis of CAD and its potential to serve as a novel biomarker.
Author Disclosures: P. Agasthi: None. S. Aloor: None. M. Axiyan: None. A. Onwuanyi: None.
- © 2015 by American Heart Association, Inc.